Biotech · Private company
Hansa Biopharma AB
Track this companyFree. Adds Hansa Biopharma AB to your Dealase workspace and tells you when its record changes.
Clinical trials81 recruiting or active
Pipeline programs17From trials and the company's site
Disclosed deals0None found yet
Cash runwayNot availablePrivate: no SEC financials
Pipeline17
- Anti-CD20 antibodiesPhase 3 · Kidney Transplantation in Highly Sensitized PatientsClinicalTrials.gov · fetched Nov 12, 2026
- Cyclophosphamide (CYC)Phase 3 · Anti-Glomerular Basement Membrane DiseaseClinicalTrials.gov · fetched Nov 12, 2026
- EculizumabPhase 3 · Kidney Transplantation in Highly Sensitized PatientsClinicalTrials.gov · fetched Nov 12, 2026
- GlucocorticoidsPhase 3 · Anti-Glomerular Basement Membrane DiseaseClinicalTrials.gov · fetched Nov 12, 2026
- ImlifidasePhase 3 · Kidney Transplantation in Highly Sensitized PatientsClinicalTrials.gov · fetched Nov 12, 2026
- ImlifidasePhase 3 · Anti-Glomerular Basement Membrane DiseaseClinicalTrials.gov · fetched Nov 12, 2026
- IVIgPhase 3 · Kidney Transplantation in Highly Sensitized PatientsClinicalTrials.gov · fetched Nov 12, 2026
- Plasma exchange (PLEX)Phase 3 · Anti-Glomerular Basement Membrane DiseaseClinicalTrials.gov · fetched Nov 12, 2026
- PLEXPhase 3 · Kidney Transplantation in Highly Sensitized PatientsClinicalTrials.gov · fetched Nov 12, 2026
- Remain on wait listPhase 3 · Kidney Transplantation in Highly Sensitized PatientsClinicalTrials.gov · fetched Nov 12, 2026
- IdeSPhase 2 · Kidney Failure, ChronicClinicalTrials.gov · fetched Nov 12, 2026
- ImlifidasePhase 2 · Kidney Transplant RejectionClinicalTrials.gov · fetched Nov 12, 2026
- Kidney transplantationPhase 2 · Kidney Failure, ChronicClinicalTrials.gov · fetched Nov 12, 2026
- Plasma ExchangePhase 2 · Kidney Transplant RejectionClinicalTrials.gov · fetched Nov 12, 2026
- Best available treatment administered in the ConfIdeS studyKidney Transplantation in Highly Sensitized PatientsClinicalTrials.gov · fetched Nov 12, 2026
- ImlifidaseKidney Transplant Failure and RejectionClinicalTrials.gov · fetched Nov 12, 2026
- Imlifidase administered in the ConfIdeS studyKidney Transplantation in Highly Sensitized PatientsClinicalTrials.gov · fetched Nov 12, 2026
Clinical trials8
- Survival and Dialysis Independency in Highly Sensitized Patients After Desensitization With Imlifidase and Tx of KidneysACTIVE_NOT_RECRUITING · started Apr 21, 2023ClinicalTrials.gov NCT05714514 · fetched Nov 12, 2026
- A Study With Imlifidase in Anti-GBM DiseasePHASE3 · TERMINATED · started Dec 22, 2022ClinicalTrials.gov NCT05679401 · fetched Nov 12, 2026
- A Study to Investigate DSA Rebound in Patients Treated With Imlifidase Prior to TransplantationPHASE2 · TERMINATED · started Dec 16, 2022ClinicalTrials.gov NCT05049850 · fetched Nov 12, 2026
- Renal Function in Highly Sensitized Patients 1 Year After Desensitization With Imlifidase Prior to DD Kidney TxPHASE3 · COMPLETED · started Oct 14, 2021ClinicalTrials.gov NCT04935177 · fetched Nov 12, 2026
- An Efficacy and Safety Study of Imlifidase in Treatment of Antibody-Mediated Rejection in Kidney Transplant PatientsPHASE2 · COMPLETED · started Apr 30, 2019ClinicalTrials.gov NCT03897205 · fetched Nov 12, 2026
- A Follow up Study of Patients Treated With Imlifidase Prior to Kidney TransplantationCOMPLETED · started Jun 27, 2018ClinicalTrials.gov NCT03611621 · fetched Nov 12, 2026
- A Phase II Study to Evaluate the Efficacy of IdeS to Desensitize Transplant Patients With a Positive Crossmatch TestPHASE2 · COMPLETED · started Jun 1, 2016ClinicalTrials.gov NCT02790437 · fetched Nov 12, 2026
- Ides in Highly Sensitized (HS) Patients Awaiting Kidney TransplantationPHASE1_PHASE2 · COMPLETED · started Jun 16, 2015ClinicalTrials.gov NCT02426684 · fetched Nov 12, 2026